45.59 USD
-0.67 (-1.45%)
45.6 USD
+0.01 (+0.02%)
SUPN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of SUPN get a neutral evaluation. Nothing too spectacular is happening here. SUPN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
SUPN had positive earnings in the past year.
In the past year SUPN had a positive cash flow from operations.
In the past 5 years SUPN has always been profitable.
SUPN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -1.35%, SUPN is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
SUPN has a better Return On Equity (-1.82%) than 77.60% of its industry peers.
With a decent Return On Invested Capital value of 2.34%, SUPN is doing good in the industry, outperforming 79.69% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for SUPN is significantly below the industry average of 12.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.35% | ||
| ROE | -1.82% | ||
| ROIC | 2.34% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
1.3 Margins
SUPN's Profit Margin has declined in the last couple of years.
SUPN has a better Operating Margin (6.08%) than 79.17% of its industry peers.
In the last couple of years the Operating Margin of SUPN has declined.
Looking at the Gross Margin, with a value of 89.91%, SUPN belongs to the top of the industry, outperforming 92.19% of the companies in the same industry.
In the last couple of years the Gross Margin of SUPN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.08% | ||
| PM (TTM) | N/A | ||
| GM | 89.91% |
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SUPN is destroying value.
The number of shares outstanding for SUPN has been increased compared to 1 year ago.
The number of shares outstanding for SUPN has been increased compared to 5 years ago.
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 5.61 indicates that SUPN is not in any danger for bankruptcy at the moment.
SUPN has a Altman-Z score of 5.61. This is in the better half of the industry: SUPN outperforms 77.60% of its industry peers.
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.61 |
ROIC/WACC0.26
WACC8.89%
2.3 Liquidity
A Current Ratio of 1.80 indicates that SUPN should not have too much problems paying its short term obligations.
The Current ratio of SUPN (1.80) is worse than 65.63% of its industry peers.
SUPN has a Quick Ratio of 1.56. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
SUPN has a worse Quick ratio (1.56) than 60.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.56 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 0.32% over the past year.
SUPN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.93% yearly.
The Revenue has been growing slightly by 4.54% in the past year.
Measured over the past years, SUPN shows a quite strong growth in Revenue. The Revenue has been growing by 11.00% on average per year.
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
3.2 Future
SUPN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.52% yearly.
Based on estimates for the next years, SUPN will show a quite strong growth in Revenue. The Revenue will grow by 14.90% on average per year.
EPS Next Y-8.49%
EPS Next 2Y2.48%
EPS Next 3Y10.42%
EPS Next 5Y19.52%
Revenue Next Year9.29%
Revenue Next 2Y15.81%
Revenue Next 3Y15.03%
Revenue Next 5Y14.9%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 14.71, which indicates a correct valuation of SUPN.
Based on the Price/Earnings ratio, SUPN is valued cheaply inside the industry as 86.46% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of SUPN to the average of the S&P500 Index (26.31), we can say SUPN is valued slightly cheaper.
The Price/Forward Earnings ratio is 14.71, which indicates a correct valuation of SUPN.
SUPN's Price/Forward Earnings ratio is rather cheap when compared to the industry. SUPN is cheaper than 82.29% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.59. SUPN is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.71 | ||
| Fwd PE | 14.71 |
4.2 Price Multiples
SUPN's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. SUPN is cheaper than 79.69% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SUPN is valued a bit cheaper than the industry average as 78.13% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.95 | ||
| EV/EBITDA | 17.67 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)2.12
EPS Next 2Y2.48%
EPS Next 3Y10.42%
5. Dividend
5.1 Amount
SUPN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
45.59
-0.67 (-1.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners109.54%
Inst Owner Change-3.26%
Ins Owners4.2%
Ins Owner Change2.53%
Market Cap2.61B
Revenue(TTM)681.54M
Net Income(TTM)-19.12M
Analysts83.33
Price Target61.71 (35.36%)
Short Float %8.07%
Short Ratio5.47
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.78%
Min EPS beat(2)67.83%
Max EPS beat(2)87.73%
EPS beat(4)4
Avg EPS beat(4)62.07%
Min EPS beat(4)15.55%
Max EPS beat(4)87.73%
EPS beat(8)7
Avg EPS beat(8)65.74%
EPS beat(12)9
Avg EPS beat(12)51.6%
EPS beat(16)10
Avg EPS beat(16)29.18%
Revenue beat(2)2
Avg Revenue beat(2)5.28%
Min Revenue beat(2)5.28%
Max Revenue beat(2)5.29%
Revenue beat(4)3
Avg Revenue beat(4)4.96%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)9.98%
Revenue beat(8)6
Avg Revenue beat(8)5.09%
Revenue beat(12)8
Avg Revenue beat(12)3.15%
Revenue beat(16)11
Avg Revenue beat(16)2.6%
PT rev (1m)38.13%
PT rev (3m)50.5%
EPS NQ rev (1m)-57.92%
EPS NQ rev (3m)-54.44%
EPS NY rev (1m)17.89%
EPS NY rev (3m)55.99%
Revenue NQ rev (1m)-3.29%
Revenue NQ rev (3m)4.99%
Revenue NY rev (1m)0.91%
Revenue NY rev (3m)9.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.71 | ||
| Fwd PE | 14.71 | ||
| P/S | 3.84 | ||
| P/FCF | 36.95 | ||
| P/OCF | 36.37 | ||
| P/B | 2.49 | ||
| P/tB | 8.51 | ||
| EV/EBITDA | 17.67 |
EPS(TTM)3.1
EY6.8%
EPS(NY)3.1
Fwd EY6.8%
FCF(TTM)1.23
FCFY2.71%
OCF(TTM)1.25
OCFY2.75%
SpS11.89
BVpS18.31
TBVpS5.36
PEG (NY)N/A
PEG (5Y)2.12
Graham Number35.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.35% | ||
| ROE | -1.82% | ||
| ROCE | 3.81% | ||
| ROIC | 2.34% | ||
| ROICexc | 3.16% | ||
| ROICexgc | 38.99% | ||
| OM | 6.08% | ||
| PM (TTM) | N/A | ||
| GM | 89.91% | ||
| FCFM | 10.38% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
ROICexc(3y)4.39%
ROICexc(5y)6.6%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.82%
ROCE(5y)7.36%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y11.61%
ROICexc growth 5Y-8.56%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
F-Score4
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1.32% | ||
| Cap/Sales | 0.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 56.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.56 | ||
| Altman-Z | 5.61 |
F-Score4
WACC8.89%
ROIC/WACC0.26
Cap/Depr(3y)0.67%
Cap/Depr(5y)5.39%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.25%
Profit Quality(3y)2940.94%
Profit Quality(5y)1832.68%
High Growth Momentum
Growth
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
EPS Next Y-8.49%
EPS Next 2Y2.48%
EPS Next 3Y10.42%
EPS Next 5Y19.52%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
Revenue Next Year9.29%
Revenue Next 2Y15.81%
Revenue Next 3Y15.03%
Revenue Next 5Y14.9%
EBIT growth 1Y-47.81%
EBIT growth 3Y-5.79%
EBIT growth 5Y-9.43%
EBIT Next Year-16.93%
EBIT Next 3Y25.95%
EBIT Next 5Y32.85%
FCF growth 1Y-23.92%
FCF growth 3Y11.03%
FCF growth 5Y4.05%
OCF growth 1Y-23.21%
OCF growth 3Y10.6%
OCF growth 5Y3.74%
SUPERNUS PHARMACEUTICALS INC / SUPN FAQ
Can you provide the ChartMill fundamental rating for SUPERNUS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 5 / 10 to SUPN.
Can you provide the valuation status for SUPERNUS PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 5 / 10 to SUPERNUS PHARMACEUTICALS INC (SUPN). This can be considered as Fairly Valued.
What is the profitability of SUPN stock?
SUPERNUS PHARMACEUTICALS INC (SUPN) has a profitability rating of 5 / 10.
What is the valuation of SUPERNUS PHARMACEUTICALS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SUPERNUS PHARMACEUTICALS INC (SUPN) is 14.71 and the Price/Book (PB) ratio is 2.49.
How financially healthy is SUPERNUS PHARMACEUTICALS INC?
The financial health rating of SUPERNUS PHARMACEUTICALS INC (SUPN) is 6 / 10.